Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Hepatitis B Reactivation: Patient and Physician Sharing Session #4

Source: Addressing Misunderstandings in Applying HBV Treatment Guidelines
In episode 4 of this ongoing series, listen to a conversation between Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, and his patient Mark, who presented with hepatitis B after receiving immunomodulatory treatment for rheumatoid arthritis.
Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA)
Released: July 26, 2021

In episode 4 of an ongoing series of sharing sessions between a physician and patient, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses hepatitis B diagnosis and treatment with his patient, Mark. The conversation focuses on Mark’s missed HBV diagnosis and likely reactivation following treatment for rheumatoid arthritis and raises awareness for needed improvements to communication between multidisciplinary healthcare teams.

Information on this Educational Activity

Faculty

Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA)

Emeritus Professor of Medicine
Consultant Hepatologist
University College London Medical School
Professor
Liver Unit
Kings College Hospital
London, United Kingdom

Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA), has disclosed that he has received funds for research support from Abbott and consulting fees from Antios, Gilead Sciences, GlaxoSmithKline, Janssen, Lumira, Myr, and Roche.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Clinical Care Options (CCO) expert commentary from Maria Buti, MD, on her approach to assessing patients with HBV for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

Clinical Care Options (CCO) expert commentary from George Lau, MD, on the importance of screening patients for hepatitis B prior to immunosuppressive therapy initiation

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: August 23, 2021

Dr. Takeshi Saito on increasing detection of HBV/HDV coinfection, especially among HBsAg-positive persons, examples from Mongolian population in California from Clinical Care Options (CCO)

person default Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 20, 2021 Expired: August 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue